Viewing nowCombinationEmpavex Tablets 5/500 mg (Empagliflozin, Metformin Hydrochloride)
Empagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Seoul Pharmaceutical Co., Ltd.

MFDS item code 202501669 · Approved 2025.07.04 · Insurance code 652904740
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is a combination therapy using Empagliflozin and Metformin to help improve blood glucose control in adults with type 2 diabetes. It is primarily administered as an adjunct to dietary and exercise therapy. It can also be used in cases where blood glucose is not adequately controlled in adults with type 2 diabetes who have cardiovascular disease; in such cases, it is essential to refer to professional information regarding its impact on cardiovascular events. This drug enhances blood sugar control and is effectively used in the treatment of type 2 diabetes.
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: empagliflozin 25 mg and metformin 2000 mg. For patients who do not achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current dose of metformin. If the patient tolerates empagliflozin 10 mg (total daily dose) well but requires additional glycemic control, the dose may be increased to empagliflozin 25 mg (total daily dose). Patients switching to this medicine from concomitant therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive the same doses of empagliflozin and metformin as they were previously taking. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see sections 4. Adverse Reactions and 6. Interactions under Precautions for Use). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take twice the dose at one time; in this case, skip the missed dose. No dose adjustment is necessary for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be monitored carefully every 3-6 months (see section 3. Patients Requiring Caution in Use, item 1) under Precautions for Use). If renal function declines to CrCl <45 ml/min or eGFR <45 ml/min/1.73m2, this medicine should be discontinued immediately (see section 2. Patients in Whom This Medicine Must Not Be Used, item 2) under Precautions for Use). In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.
This medication helps control blood sugar, but there are several precautions to be aware of during use. First, this drug can cause a rare side effect of serious lactic acidosis, so it should not be used in individuals with poor kidney function or those with severe infections, dehydration, or heart problems. Additionally, when used in conjunction with insulin or other diabetes medications, there is a risk of hypoglycemia, so blood sugar should be closely monitored. Particularly, this medicine should not be administered to patients with moderate or severe renal impairment, acute kidney issues, heart failure, or severe liver dysfunction. Before and after tests using iodinated contrast agents, this medication should be temporarily discontinued due to the risk of kidney damage and lactic acidosis, and it can be resumed once kidney function has returned to normal. Pregnant or breastfeeding women are advised against using this medication, and it is not recommended for children under 18 years of age as safety and efficacy have not been established. In elderly patients, kidney function may decline, so renal function should be checked prior to administration and monitored regularly, and excessive dosing should be avoided. If symptoms such as dehydration, vomiting, or diarrhea occur while taking this medication, immediate consultation with a physician is necessary, and alcohol consumption should be avoided as it may increase the risk of lactic acidosis. Additionally, this drug may increase the risk of urinary tract infections or genital infections, so prompt treatment should be sought if infection symptoms develop. Vitamin B12 deficiency may occur; therefore, if used for an extended period, regular monitoring of vitamin B12 levels is needed. Finally, this medication may interact with other drugs that can affect blood sugar control, so it is vital to inform a doctor or pharmacist of any other medications being taken.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. It is advisable to maintain storage temperatures between 1 and 30 degrees Celsius at room temperature. This will help ensure the medication's effectiveness is safely preserved.
Orange-yellow, biconvex oval film-coated tablet
60 tablets/bottle, 60 tablets/box [10 tablets/PTP x 6]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Seoul Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.